Chikungunya Fever Clinical Trial
Official title:
Effects of Auriculotherapy on Pain and Functional Capacity of Individuals With Chikungunya Fever
Verified date | October 2018 |
Source | Universidade Federal do Ceara |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Chikungunya fever is an acute viral disease, transmitted by the mosquito (Aedes aegypti),
that triggers pain and disabling rheumatic manifestations. There is no cure for this disease,
and the usual treatment is directed at relieving symptoms through the use of analgesics and
antipyretics. Due to the risk of adverse effects triggered by prolonged use of analgesic and
anti-inflammatory drugs, the use of complementary therapies, such as Auriculotherapy, might
be a safe and effective non-pharmacological treatment for the management of Chikungunya
symptomatic cases.
Subjects diagnosed with Chikungunya and undergoing routine treatment will receive
auricotherapy treatment once a week, for five weeks. Subjects will be assessed at baseline
and after 4 and 8 weeks after intervention. This study might help understand the use of
Auriculotherapy as a complementary treatment in the treatment of physical and functional
symptoms of individuals infected by Chikungunya .
Status | Completed |
Enrollment | 50 |
Est. completion date | November 1, 2017 |
Est. primary completion date | November 1, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility |
Inclusion Criteria: - individuals aged = 18 years; - with medical or other referral from the Family Health Strategy due to symptoms resulting from Chikungunya fever confirmed by clinical or laboratory criteria; - be able to understand instructions and answer the questions asked by the interviewer. Exclusion Criteria: - complaints of pain unrelated to the lower limbs; - presence of malignant neoplastic disease; - history of traumatic injury or the lower limb and surgery in the last 12 months; - congenital deformation; - pregnancy; - history of treatment with with Auriculotherapy, acupuncture or physiotherapy in the last four weeks; - use of steroid medication in the last month; - use of opioids during the study period; - do not sign the Free and Informed Consent Form (TCLE). |
Country | Name | City | State |
---|---|---|---|
Brazil | Grupo de Atenção Integral e Pesquisa em Acupuntura e Medicina Tradicional Chinesa - GAIPA | Fortaleza | Ceará |
Lead Sponsor | Collaborator |
---|---|
Universidade Federal do Ceara |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pain Numerical rating scale (NRS) | Graded scale from 0 (no pain) to 10 (worst pain imaginable) that evaluates in one-dimensional the perception of pain by asking about the average pain felt in the past seven days in the symptomatic limb. | collected at baseline up to 2 months after therapy | |
Primary | Timed Up and Go Test (TUG) | Performance-based test designed to assess functional mobility and risk of falls in frail older adults.This instrument has been associated with other to test musculoskeletal conditions. | collected at baseline up to 2 months after therapy | |
Secondary | World Health Disability Assessment Schedule (WHODAS 2.0) | Generic instrument with high internal consistency (a: 0.86), high test-retest reliability (ICC: 0.98) that evaluates deficiency and functionality based on six domains (cognition, mobility, self-care, interpersonal relations, life activity and participation). | collected at baseline up to 2 months after therapy | |
Secondary | Short Physical Performance Battery (SPPB) | Test consisted of thress sub-tests that assess the functional capacity of the lower limbs, through static balance, gait speed and lower limb muscle strength. | collected at baseline up to 2 months after therapy | |
Secondary | Reducing the use of pain medication | Patient self-report on the use of analgesic and anti-inflammatory drugs, by recording the dosage and type of medication. | collected at baseline up to 2 months after therapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03055585 -
Applying Wolbachia to Eliminate Dengue
|
N/A | |
Withdrawn |
NCT02714985 -
RT-PCR on Urine Samples: Added Value for the Diagnosis of Chikungunya Virus Infection
|
||
Completed |
NCT02901509 -
Impact of the Chikungunya Outbreak in Reunion Island on the Quality of Life After 10 Years
|
||
Completed |
NCT03590392 -
Safety and Immunogenicity of a Candidate CHIKV Vaccine (CHIK001)
|
Phase 1 | |
Active, not recruiting |
NCT03702348 -
Resistance Exercise Program on the Functionality of Individuals With Chikungunya Fever
|
Early Phase 1 | |
Not yet recruiting |
NCT04235361 -
Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC
|
||
Completed |
NCT03206541 -
Neurologic Manifestations of the Arbovirus Infection in Colombia
|
||
Completed |
NCT06268691 -
Sustainable Reduction of Dengue in Colombia: Vector Breeding Site Intervention With an Insecticidal Coating
|
N/A | |
Completed |
NCT01489358 -
Chikungunya Virus Vaccine Trial in Healthy Adults
|
Phase 1 | |
Completed |
NCT02993952 -
tDCS and Its Therapeutic Effects in CK Fever
|
N/A | |
Completed |
NCT03690648 -
Genetic Factors and Immunological Determinism of Persistent Consequences of Chikungunya
|
||
Completed |
NCT02174341 -
The Pilot Study of Chikungunya Virus Infections in Southern Taiwan
|